First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search DSpace



Browse

My Account

Statistics